Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 3Neoplasms 2Synovial Cyst 1Spondylosis 1Spondylolisthesis 1Spinal Stenosis 1Radiculopathy 1Pilonidal Sinus 1Pain, Postoperative 1Neoplasms, Second Primary 1Musculoskeletal Diseases 1Malignant Neoplasms of Male Genital Organs 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hot Flashes 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Agnosia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Clonidine × Clear all
NCT04030572 2021-06-24

a2a Agonist

Weill Medical College of Cornell University

Phase EARLY_PHASE1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasms

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡